A new pill which could "significantly improve" survival times for those with advanced kidney cancer has been licensed for the UK following a global trial.
Patients at 173 centres across the world, including 10 in the UK, were treated with Cabometyx, which is also known as cabozantinib.
A total of 658 patients with advanced renal cell carcinoma (RCC) were involved, with pharmaceutical firm Ipsen claiming results showed a 34% reduction in the rate of death, with sufferers living up to two years longer.
READ MORE: Leukaemia breakthrough to help thousands with disease
Professor Robert Jones, of the Institute of Cancer Sciences at Glasgow University, said the disease was becoming "increasingly common".
He stated: "Although many cases are diagnosed at a sufficiently early stage to allow curative surgery, unfortunately in many cases the disease has already spread at the time of diagnosis and, even after surgery, the cancer can come back in a more lethal form.
"Although treatments for incurable renal cancer have greatly improved in the last 10 years, unfortunately in most cases current treatments will eventually stop working.
"Cabozantinib is a new, tablet-based treatment which significantly improves survival times and delays the time to the development of new problems for these patients.
"The licensing of this drug is particularly meaningful for patients in Scotland as patients in Glasgow took part in the clinical trial which showed that it works."
READ MORE: Leukaemia breakthrough to help thousands with disease
Nick Turkentine, chief executive of the Kidney Cancer UK charity, said: "As the eighth most common cancer in the UK, it is important that we continue to make advances in the management of kidney cancer, in particular in RCC where outcomes are still poor as many patients are diagnosed when their disease has become advanced."
Professor Robert Hawkins, director of medical oncology at the University of Manchester and the city's Christie Hospital, was also involved in the drug trial.
He said: "Over the past 20 years, rates of kidney cancer in the UK have increased by around 70%, one of the most rapidly-increasing cancers.
"When renal cell carcinoma spreads outside of the kidney or metastasises to other parts of the body, it is referred to as advanced RCC and then it becomes increasingly hard to treat.
"Cabometyx gives us an effective further treatment option to treat those patients with advanced RCC who have stopped responding to previous treatment."
READ MORE: Leukaemia breakthrough to help thousands with disease
Ewan McDowall, vice president commercial operations for Ipsen UK & Ireland, said: "We are delighted that Cabometyx has been granted a licence for use in the UK."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here